TrialAutopsyBuilt by Jawad Momani (Pwnedl0l)

Autopsy report · NCT02470559

Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent

Cause of deathStaffing, sites or logistics, also slow enrollment Automatic label, confidence 0.5, unverified. How labels are made.
“Study did not accrue any participants, the PI has left the institution.”

The sponsor’s own words in the registry.

Life of this trial

201520162017Registered2015-06-10Planned start2015-06 (planned)Withdrawn (as of)2016-02-17

Vital statistics

Status
Withdrawn
Phase
Phase 1
Sponsor
Barbara Ann Karmanos Cancer Institute
Sponsor type
University, hospital or other
Conditions
Malignant Ovarian Clear Cell Tumor; Malignant Ovarian Serous Tumor; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Stage IIIA Fallopian Tube Cancer
Interventions
Aldesleukin; HER2Bi-Armed Activated T Cells; Laboratory Biomarker Analysis; Sargramostim
Participants
0

Trials that died the same way

Look deeper

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.